OBJECTIVE: To determine the efficacy of pazopanib eye drops in the streptozotocin induced diabetic retinopathy rat model. METHODS: A 0.5% w/v pazopanib suspension was prepared in phosphate buffered saline (PBS, pH 7.4) in the presence of 0.5% w/v sodium carboxymethyl cellulose. Brown Norway rats were divided into three groups (n=4) - (1) healthy, (2) diabetic, and (3) diabetic with treatment. The drug suspension was administered twice daily as eye drops to group 3 for 30 days. Efficacy parameters including the number of adherent leukocytes in the retinal vasculature (leukostasis), blood-retinal FITC-dextran leakage, and vitreous-to-plasma protein ratio were measured. RESULTS: Pazopanib suspension in the form of eye drops significantly reduced leukostasis (32%), FITC-dextran leakage (39%), and the vitreous-to-plasma protein ratio (64%) in diabetic animals compared to untreated diabetic group. CONCLUSION: Pazopanib eye drops can alleviate retinal complications of diabetic retinopathy.
OBJECTIVE: To determine the efficacy of pazopanib eye drops in the streptozotocin induced diabetic retinopathyrat model. METHODS: A 0.5% w/v pazopanib suspension was prepared in phosphate buffered saline (PBS, pH 7.4) in the presence of 0.5% w/v sodium carboxymethyl cellulose. Brown Norway rats were divided into three groups (n=4) - (1) healthy, (2) diabetic, and (3) diabetic with treatment. The drug suspension was administered twice daily as eye drops to group 3 for 30 days. Efficacy parameters including the number of adherent leukocytes in the retinal vasculature (leukostasis), blood-retinal FITC-dextran leakage, and vitreous-to-plasma protein ratio were measured. RESULTS:Pazopanib suspension in the form of eye drops significantly reduced leukostasis (32%), FITC-dextran leakage (39%), and the vitreous-to-plasma protein ratio (64%) in diabetic animals compared to untreated diabetic group. CONCLUSION:Pazopanib eye drops can alleviate retinal complications of diabetic retinopathy.
Authors: T Qaum; Q Xu; A M Joussen; M W Clemens; W Qin; K Miyamoto; H Hassessian; S J Wiegand; J Rudge; G D Yancopoulos; A P Adamis Journal: Invest Ophthalmol Vis Sci Date: 2001-09 Impact factor: 4.799
Authors: Yousef Yafai; Xiu Mei Yang; Marc Niemeyer; Akiko Nishiwaki; Johannes Lange; Peter Wiedemann; Andrew G King; Tsutomu Yasukawa; Wolfram Eichler Journal: Eur J Pharmacol Date: 2011-05-20 Impact factor: 4.432
Authors: Francisco Amparo; Zahra Sadrai; Yiping Jin; Belen Alfonso-Bartolozzi; Haobing Wang; Hasanain Shikari; Joseph B Ciolino; James Chodosh; Ula Jurkunas; Debra A Schaumberg; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2013-01-17 Impact factor: 4.799
Authors: Takeshi Iwase; Brian C Oveson; Noriyasu Hashida; Raquel Lima e Silva; Jikui Shen; Achim H Krauss; David C Gale; Peter Adamson; Peter A Campochiaro Journal: Invest Ophthalmol Vis Sci Date: 2013-01-21 Impact factor: 4.799